RxDoctor Payments Data

Julie Mazur

Family · Pittsburgh, PANPI 1396529046

Payments from drug & device makers

$2,873in general payments, 2019–2025

Across 118 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$834
  • Axsome Therapeutics, Inc.$256
  • Gynesonics, Inc.$126
  • Lundbeck LLC$114

What the payments were for

  • Food & beverage$2,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie70$1,543
Pfizer40$834
Axsome Therapeutics, Inc.6$256
Gynesonics, Inc.1$126
Lundbeck LLC1$114

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,873 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,897
Medicare patients
51
Services billed
10,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate45$63,751
UbrelvyUbrogepant44$59,458
QuliptaAtogepant31$37,195
Emgality PenGalcanezumab-Gnlm31$22,712
ReyvowLasmiditan Succinate25$16,556
Lacosamide23$1,356
RizatriptanRizatriptan Benzoate26$515
Duloxetine Hcl29$371
Sumatriptan Succinate20$370
Lamotrigine12$248
Nortriptyline Hcl19$248
Topiramate37$233
Prochlorperazine Maleate23$186
Gabapentin28$185
Clonazepam13$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,543$96,65375 claims
PfizerNurtec Odt$834$63,75145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →